Han-Joon Kim1, Beomseok Jeon2, Junghan Song3, Woong-Woo Lee4, Hyeyoung Park1, Chae-Won Shin1. 1. Department of Neurology and Movement Disorder Center, Parkinson Study Group, and Neuroscience Research Institute, College of Medicine, Seoul National University, Seoul, South Korea. 2. Department of Neurology and Movement Disorder Center, Parkinson Study Group, and Neuroscience Research Institute, College of Medicine, Seoul National University, Seoul, South Korea. Electronic address: brain@snu.ac.kr. 3. Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea; Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. 4. Department of Neurology, Eulji General Hospital, Seoul, South Korea.
Abstract
BACKGROUND: Recent reports have shown that the activities of lysosomal enzymes are altered in the CNS of sporadic PD (sPD) without GBA mutations. We hypothesized that the activities of lysosomal enzymes are altered in peripheral blood leukocytes (PBLs) of patients with sPD and other genetic parkinsonism. METHODS: Glucocerebrosidase and β-hexosaminidase activities in PBLs were measured in 36 patients with sPD, 5 PD patients with PARK2 mutations, 10 patients with spinocerebellar ataxia (SCA) 17 with parkinsonism, and 20 healthy controls. RESULTS: The glucocerebrosidase and β-hexosaminidase activities were not different in patients with sPD, PD with PARK2 mutations, and SCA17 with parkinsonism from those of the controls. In the patients with sPD, the activity of GCase was positively correlated with disease duration. CONCLUSION: The glucocerebrosidase and β-hexosaminidase activities in PBLs cannot be used as a biomarker in sPD and other genetic parkinsonism.
BACKGROUND: Recent reports have shown that the activities of lysosomal enzymes are altered in the CNS of sporadic PD (sPD) without GBA mutations. We hypothesized that the activities of lysosomal enzymes are altered in peripheral blood leukocytes (PBLs) of patients with sPD and other genetic parkinsonism. METHODS:Glucocerebrosidase and β-hexosaminidase activities in PBLs were measured in 36 patients with sPD, 5 PDpatients with PARK2 mutations, 10 patients with spinocerebellar ataxia (SCA) 17 with parkinsonism, and 20 healthy controls. RESULTS: The glucocerebrosidase and β-hexosaminidase activities were not different in patients with sPD, PD with PARK2 mutations, and SCA17 with parkinsonism from those of the controls. In the patients with sPD, the activity of GCase was positively correlated with disease duration. CONCLUSION: The glucocerebrosidase and β-hexosaminidase activities in PBLs cannot be used as a biomarker in sPD and other genetic parkinsonism.
Authors: Robin B Chan; Adler J Perotte; Bowen Zhou; Christopher Liong; Evan J Shorr; Karen S Marder; Un J Kang; Cheryl H Waters; Oren A Levy; Yimeng Xu; Hong Bin Shim; Itsik Pe'er; Gilbert Di Paolo; Roy N Alcalay Journal: PLoS One Date: 2017-02-17 Impact factor: 3.240
Authors: Melinda Barkhuizen; David G Anderson; Francois H van der Westhuizen; Anne F Grobler Journal: Mol Genet Genomic Med Date: 2017-02-08 Impact factor: 2.183
Authors: Farzaneh Atashrazm; Deborah Hammond; Gayathri Perera; Carol Dobson-Stone; Nicole Mueller; Russell Pickford; Woojin Scott Kim; John B Kwok; Simon J G Lewis; Glenda M Halliday; Nicolas Dzamko Journal: Sci Rep Date: 2018-10-18 Impact factor: 4.379
Authors: Laura P Hughes; Marilia M M Pereira; Deborah A Hammond; John B Kwok; Glenda M Halliday; Simon J G Lewis; Nicolas Dzamko Journal: J Parkinsons Dis Date: 2021 Impact factor: 5.568